|
FDA to Hold Stakeholder Meetings on Developing Biosimilar User Fees
The FDA is planning to hold consultation meetings with drugmakers and other industry stakeholders to seek their views on the development of a user fee program for biosimilars.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives